Paul Richardson

Experts discuss integrating BCMA-directed agents in MM treatment, challenges of CAR T-cell availability, potential of bispecific therapies, and ADCs. Emphasis on managing keratopathy, high response rates with combination therapies, and the importance of evaluating BCMA-directed agents in earlier lines of therapy.

Dr. Paul G. Richardson, a leading expert in multiple myeloma from Dana-Farber, shares his insights on innovative treatment strategies involving XPO1 inhibition. He dives into the evolution of selinexor, discussing its flexible use in relapsed multiple myeloma cases, particularly how it can serve as a bridge to CAR T therapies. Dr. Richardson highlights real-world patient scenarios and emphasizes the importance of personalized treatment plans to optimize outcomes. He also reveals promising data on selinexor in combination with emerging therapies, showcasing its potential for rapid responses.

In this engaging discussion, Prof. Philippe Moreau from France, Dr. Robert Z Orlowski from MD Anderson, Dr. Noopur Raje from Massachusetts General, and Dr. Paul G Richardson delve into the complexities of managing multiple myeloma. They tackle innovative treatment strategies, including the use of CD38 antibodies, novel therapies, and the importance of minimal residual disease as a prognostic marker. The conversation also covers challenges in treating elderly patients, the role of CAR T-cell therapies, and the potential of the new BELLA drug in improving outcomes.